According to filings with the U.S. Securities and Exchange Commission, Cellares has raised $20,000,000.00 in new Series D funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Cellares
Cellares is the first Integrated Development and Manufacturing Organization (IDMO), taking an Industry 4.0 approach to the mass manufacturing of cell therapies, often called the living drugs of the 21st century. The company develops and deploys integrated technologies, including its automated Cell Shuttle platform, to industrialize and scale end-to-end cell therapy manufacturing and quality control. By combining advanced automation, software, and purpose-built facilities, Cellares aims to dramatically increase scalability, reduce process failures and costs, and make life-saving cell therapies more accessible to patients worldwide. It partners with biopharma companies and institutions to accelerate the development, tech transfer, and commercialization of cell therapies on a global scale. Positioned as a pioneer in IDMO smart factories and next-generation cell therapy manufacturing infrastructure, Cellares focuses on enabling true global patient access to these transformative treatments.

To learn more, visit https://www.cellares.com/
Linkedin: https://www.linkedin.com/company/cellares-corporation/

Contact:
Fabian Gerlinghaus, Chief Executive Officer
https://www.linkedin.com/in/fabian-gerlinghaus/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.